A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
Status:
Suspended
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The study will consist of a Screening period (up to 14 days), a Treatment period, and a
Follow-Up period. Sixteen subjects will be enrolled into two sequential dose cohorts - 10 or
30 mg (or matching placebo) across four study centers.